From MedPage Today:
- Breast Cancer: Adding Avastin Boosts Toxicity. Beleaguered bevacizumab (Avastin) has failed another test in breast cancer.
- FDA Wants Proof of Anti-Bacterial Soap Claims. Manufacturers of nonprescription anti-bacterial hand soaps and body washes will soon be required to show their products are safe for long-term daily use and are more effective than plain soap in stopping the spread of infections.